Constellation CPI-0610 demonstrates good clinical activity in Phase 2 clinical trial called MANIFEST

today, co
stellation pharmaceutical(http:// announcedthat its selective BET inhibitor CPI-0610 demonstrated good clinical activity in the clinicaltrial(http://called MANIFESTThe trial was primarily targeted at patients who had not been treated with JAK inhibitors and were resistant or intolerant to the listed therapy ruxolitinibAbout CPI-0610
Constellation'sdrug(http://CPI-0610 is a selective BET inhibitor, which reduces the expression level of abnormal expression genes by inhibiting BET, and achieves the effect of inhibiting the production of pro-inflammatory cytokinesCurrently, CPI-0610 is used in clinical trials as a single-drug therapy or in combination with JAK inhibitors for patients with bone marrow fibrosisConstellation believes that CPI-0610 has the potential to become a BET inhibitor of "Best-in-Class"In the study
patients with bone marrow fibrosis were divided into three queues in phase 2 clinical studies called MANIFEST In the 1/2 queue, patients who had previously developed resistance to resistance or intolerance to ruxolitinib received a single-drug treatment of CPI-0610 or a second-line treatment consisting of a combination of CPI-0610 and ruxolitinib, respectively 　　As of June 27, 2019, CPI-0610 showed good clinical activity in the treatment of patients with bone marrow fibrosis The volume of the spleen decreased, the hemoglobin content increased, and the comprehensive score of bone marrow fibrosis and the symptoms of the disease were improved In addition, four blood transfusion-dependent patients reached a state of non-dependence on blood transfusions 　　In The 3rd queue, patients who had not previously been treated with JAK inhibitors received first-line treatment of cpi-0610 and ruxolitinib combination therapy 　　Trial data showed that the spleen volume of the four assessable patients decreased by at least 35 percent, and the syndrome syndrome syndrome score decreased by 50 percent, reaching the primary therapeutic end of the patient subgroup